Table 3. OD and A% values of COX-2 immunohistochemicaly stained cortical and hippocampal sections.
| Groups | OD | A% | ||
|---|---|---|---|---|
| Cortex | Hippocampus | Cortex | Hippocampus | |
| Sham | 1.36±0.098 | 1.26±0.049 | 22.23±1.5 | 23.4±2.3 |
| Control | 1.2±0.07 | 1.32±0.033 | 26.8±1.07 | 28.6±0.87 |
| 3-NPA | 1.95* , x ±0.15 | 1.78* , x ±0.03 | 38* , x ±1.15 | 56.7* , x ±1.45 |
| 17 β-estradiol+3-NPA | 1.44 # ±0.089 | 1.53±0.04 | 28 # ±1.2 | 34.2 # ±1.2 |
| Genistein (10 mg/kg)+3-NPA | 1.6±0.078 | 1.59±0.1132 | 30.2 # ±1.4 | 44.7 # ±2.57 |
| Genistein (20 mg/kg)+3-NPA | 1.4 # ±0.105 | 1.39 # ±0.087 | 28.3 # ±0.88 | 37 # ±3.1 |
| Genistein (20 mg/kg) | 1.15±0.05 | 1.19±0.009 | 19.3*±1.43 | 20.9±1.09 |
3-NPA was administered i.p. (20 mg/kg) for 4 consecutive days. 17β-estradiol (2.5 mg/kg body weight, s.c) and genistein (10 and 20 mg/kg body weight, i.p) were administered for 8 days, beginning 4 days before and continued for 4 days one hour before 3-NPA injections. Data are presented as means ±S.E.M. (n = 3).
x statistically significant compared to sham group at P< 0.05
* statistically significant compared to control group at P< 0.05
# statistically significant compared to 3-NPA-treated group at P< 0.05 (One-way ANOVA followed by Tukey test).